# 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

> **NCT05039268** · PHASE2 · COMPLETED · sponsor: **Macquarie University, Australia** · enrollment: 16 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** 3K3A-APC Protein

## Key facts

- **NCT ID:** NCT05039268
- **Lead sponsor:** Macquarie University, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-25
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-09-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039268, "3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05039268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*